Feature | July 12, 2013

Navidea Biopharmaceuticals Initiates Enrollment in Global Phase 3 Trial of NAV4694 PET Imaging Agent

Biopharmaceuticals Inc. Clinical Study Alzheimer's Beta Amyloig

July 12, 2013 — Biopharmaceuticals Inc. announced the first subject has been enrolled in its NAV4694 global, pivotal Phase 3 clinical trial. The trial will assess the safety and efficacy of NAV4694, an investigational positron emission tomography (PET) imaging agent, in detecting cerebral ?-amyloid in end-of-life subjects with and without the diagnosis of dementia. The study will examine the effectiveness of NAV4694 in detecting the presence or absence of ?-amyloid deposition in the brain by directly correlating the PET image findings during life with those of the brain tissue upon autopsy after death.

Currently, only an autopsy can confirm that a person has Alzheimer's disease. “Knowing if a patient has Alzheimer?s pathology in life would lead to improved diagnosis and patient management,” said Frederick Cope, Ph.D., FACN, senior vice president and Chief Scientific Officer at Navidea. “This study, which is designed to provide a direct comparison of patient images collected during life using a ?-amyloid PET imaging agent with postmortem histopathology findings, has the potential to aid the advancement of neurodegenerative disease research and patient care.”

“We are excited to begin this pivotal Phase 3 trial for NAV4694. We believe that ?-amyloid imaging has the potential to play an increasingly important role in clinical practice allowing for earlier diagnosis and therapeutic intervention,” said Connie Reininger, M.D., Ph.D., Navidea’s senior vice president and chief medical officer. “Results from earlier trials using NAV4694 support our conviction that the outstanding performance characteristics of this imaging biomarker, which include favorable sensitivity, specificity, rapid brain uptake and improved image clarity due to low white-matter uptake, position NAV4694 as a true ‘best-in-class’ second generation agent to aid in the diagnosis of Alzheimer’s disease and with the potential to enable diagnosis earlier in the course of disease.”

For more information: www.navidea.com

Related Content

Sponsored Content | Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
Study Demonstrates First Human Application of Novel PET Tracer for Prostate Cancer

Transaxial 11Csarcosine hybrid PET/CT showed a (triangulated) adenocarcinoma in the transition zone of the anterior right prostate gland on PET (A), CT (B), and a separately obtained T2?weighted MR sequence (C) with resulting PET/MRI registration (D). Image courtesy of M. Piert et al., University of Michigan, Ann Arbor, Mich.

News | Radiopharmaceuticals and Tracers | August 16, 2017
In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the...
PET/CT Tracer Identifies Vulnerable Lesions in Non-Small Cell Lung Cancer Patients

Example of a patient with an upper left lung NSCLC: A: FDG; B: FDG PET/CT; C: Planning radiotherapy based on FDG (66Gy) with BTVm (GTV), CTV and PTV; D: PET FMISO E: FMISO PET/CT; F: boost based on the FMISO PET (76Gy) with BTVh (biological hypoxic target volume) and PTV boost. Credit: QuantIF – LITIS EA 4108 – FR CNRS 3638, Henri Becquerel Cancer Center, Rouen, France

News | PET-CT | July 14, 2017
July 14, 2017 — Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET)...
Novel PET Tracer Detects Small Blood Clots

PET images (MIP 0-60 min) of three Cynomolgus monkeys. Strong signals are detected at the sites where inserted catheters had roughened surfaces. Almost no other background signal is visible. Only accumulation in the gallbladder becomes visible at the bottom of the image. Credit: Piramal Imaging GmbH, Berlin Germany.

News | PET Imaging | July 07, 2017
July 7, 2017 — Blood clots in veins a
Dual-Agent PET/MR With Time of Flight Detects More Cancer

Tc-99m MDP bone scan (left) is negative for osseous lesions. NaF/FDG PET/MRI (right and second slide) confirms absence of bone metastases, but shows liver metastases. Image courtesy of Stanford University.

News | PET-MRI | June 20, 2017
Simultaneous injections of the radiopharmaceuticals fluorine-18 fluorodeoxyglucose (18F-FDG) and 18F-sodium fluoride (...

While subject No. 1 (left) was judged as positive for both the neuronal injury and the amyloid load biomarker, both Alzheimer's disease biomarkers were negative in subject No. 2 (right). Image courtesy of Henryk Barthel et al., University Hospital Leipzig, Leipzig, Germany

News | PET Imaging | June 14, 2017
More people die of Alzheimer's disease than prostate and breast cancer combined. Identifying the disease before major...
News | Clinical Study | June 09, 2017
The milestone Imaging Dementia — Evidence for Amyloid Scanning (IDEAS) Study is working with government and academic...
Lantheus and GE Healthcare Sign Agreement for Worldwide Development, Commercialization of Flurpiridaz F-18
News | Radiopharmaceuticals and Tracers | May 22, 2017
May 22, 2017 — Lantheus Holdings Inc., parent company of Lantheus Medical Imaging Inc., and GE Healthcare announced t
FALCON Trial of Fluciclovine PET/CT Imaging Stops Recruitment after Successful Interim Analysis
News | Radiopharmaceuticals and Tracers | May 15, 2017
Blue Earth Diagnostics announced that the Trial Steering Committee recommended further recruitment be stopped in the...
Overlay Init